Month: May 2021

Dallas, May 26, 2021 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ: THRY) (“Thryv” or the “Company”), today announced the pricing of its previously announced underwritten public offering of 4,238,426 shares of its common stock by certain selling stockholders (the “Selling Stockholders”) at a public offering price of $23.50 per share (the “Offering”). The Offering was upsized from a previously announced offering size of 3,500,000 shares of common stock. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 635,763 shares of common stock. The Selling Stockholders will receive all of the proceeds from the Offering. Thryv is not offering any shares of its common stock in the Offering and will not receive any proceeds from the Offering, including from any exercise by the underwriters...

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, are expected to be $160.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on May 27, 2021 under the ticker symbol “DAWN.” The offering is expected to close on June 1, 2021, subject to the satisfaction...

TORONTO, May 26, 2021 (GLOBE NEWSWIRE) — Copper Lake Resources Ltd. (TSX-V: CPL, Frankfurt: W0I) (“Copper Lake” or the “Company”) announces that on May 17, 2021, it has closed the second, and final, tranche of the non-brokered private placement (the “Offering”) described in its news release of March 4, 2021. In connection with the final tranche closing of the Offering, the Company issued 100,000 flow-through units (“FT Units”) at a price of $0.065 per FT Unit and 7,455,000 non flow-through units (“NFT Units”) at a price of $0.05 per NFT Unit for gross proceeds of $379,250. Each FT Unit consists of one flow-through common share and one-half of a common share purchase warrant (a “FT Warrant”), with each Warrant being exercisable at $0.10 for 24 months. Each NFT Unit consists of one common share and one Warrant,...

CHICAGO, May 26, 2021 (GLOBE NEWSWIRE) — R1 RCM Inc. (“R1 RCM” or the “Company”) (NASDAQ: RCM) announced that it has priced the underwritten offering of 15,000,000 shares of its common stock by selling stockholders at a price to the public of $22.50 per share. The selling stockholders are TCP-ASC ACHI Series LLLP (“TCP-ASC”), a Delaware series limited liability limited partnership jointly owned by Ascension Health Alliance and investment funds affiliated with TowerBrook Capital Partners L.P., and Joseph Flanagan, the President and Chief Executive Officer of the Company. The underwriters will have a 30-day option to purchase up to an additional 2,250,000 shares of common stock from TCP-ASC. The offering is expected to close on June 1, 2021, subject to the satisfaction or waiver of customary closing conditions. R1 RCM is not selling...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia and HONG KONG, May 26, 2021 (GLOBE NEWSWIRE) — Reyna Silver Corp. (TSXV: RSLV; OTCQB: RSNVF; FRA: 4ZC) (“Reyna” or the “Company“) is pleased to announce that it has entered into an agreement with Eight Capital and Red Cloud Securities Inc. (collectively, the “Agents“) to act as co-lead agents in connection with a best efforts private placement of up to 6,025,000 units of the Company (the “Units“) at a price of C$0.83 per Unit (the “Offering Price“) for gross proceeds of up to C$5,000,750 (the “Offering“). Each Unit will be comprised of one common share of the Company (each, a “Unit Share“) and one half of one common share purchase warrant...

CUPERTINO, Calif., May 26, 2021 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, announced today the pricing of its upsized underwritten public offering of 8,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying investor warrants to purchase up to 6,000,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase 0.75 shares of common stock at a combined effective price of $3.75. The investor warrants will be immediately exercisable...

Active discussions with FDA related to COVAXIN initiated late last year Master file submitted to FDA on March 26, 2021; awaiting feedback from FDAMALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today confirmed its plan to submit its Emergency Use Authorization (EUA) application for COVAXIN to the U.S. Food & Drug Administration (FDA) in June. “Since we have been in discussions with the FDA since late last year, we do not believe that the FDA’s recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for COVAXIN as planned, which is currently in process and which we expect to submit...

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced it will be rescheduling the company’s 2021 Annual Meeting of Shareholders (the “2021 Annual Meeting”), which was previously scheduled for July 16, 2021. Once determined by the Scopus Board of Directors, the company will announce the new date, time and location of the 2021 Annual Meeting. About Scopus BioPharma Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions. The company’s lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both RNA therapy and immunotherapy by synthetically...

TORONTO, May 26, 2021 (GLOBE NEWSWIRE) — Rise Capital Corp. (TSXV: RSE) (the “Corporation“) is pleased to announce that it has successfully completed its initial public offering of 45,000,000 common shares (the “Common Shares“) at $0.20 per share for gross proceeds of $9,000,000 (the “Offering“). As a result of this issuance, the Corporation has 55,000,000 Common Shares issued and outstanding of which 10,000,000 Common Shares are subject to escrow restrictions as disclosed in the Corporation’s final prospectus dated May 6, 2021, a copy of which may be obtained at www.sedar.com. Hampton Securities Limited (the “Agent“) acted as agent for the Offering. In connection with the Offering, the Agent received a cash commission of $419,328.00, representing 6% of the gross proceeds of...